Associate Medical Director NorBalt

About the role

As Associate Medical Director for sHTG, you are accountable for defining and driving the end-to-end medical strategy for an advanced therapeutic option within rare and severe lipid disorders, including Familial Chylomicronemia Syndrome (FCS) and its potential extension into Severe Hypertriglyceridemia (sHTG).

Reporting to the Medical Director NorBalt and working in close partnership with the Medical Science Manager (MSM), you provide overarching medical leadership — setting scientific direction, steering evidence generation, and ensuring successful launch and lifecycle management.

This strategic Medical Affairs role requires deep scientific expertise, strong cross-functional collaboration, and the ability to align strategy and execution with European Medical Excellence standards, governance frameworks, and performance KPIs.

This position will be based in one of the Nordic countries.

Key Responsibilities

• Own the end-to-end medical strategy – Lead pre-launch, launch, and lifecycle planning across FCS and sHTG, ensuring scientific coherence and impact.
• Drive evidence generation & data strategy – Define and evolve the Medical Affairs Plan, overseeing RWE, ISS, NIS, HEOR, and disease-understanding initiatives with scientific rigor and compliance.
• Lead scientific engagement – Shape KOL strategy, sponsor advisory boards and congress activities, and act as senior medical expert internally and externally.
• Ensure medical content excellence – Oversee scientific narrative, publications planning, and medical materials with high standards of accuracy and clarity.
• Strengthen cross-functional partnership – Represent Medical strategically across Commercial, Market Access, Regulatory, Clinical Development, and Patient Advocacy teams.
• Champion Medical Excellence & governance – Implement planning standards, KPI tracking, compliance oversight, and continuous improvement initiatives.
• Drive launch readiness & lifecycle expansion – Ensure medical leadership during launch and support future indication development.